2014国际临床和转化医学论坛

Dmitry Samarsky, PhD

   2014-07-11
字体大小:

Dmitry Samarsky, PhD

Executive Vice President of Technology and Business Development, RiboBio, China
Dmitry Samarsky earned his PhD in biochemistry and molecular biology at University of Massachusetts, Amherst, and from 1998 to 2001 he held H. Arthur Smith Fellowship for Cancer Research at Dr. Michael Green’s laboratory, HHMI/University of Massachusetts Medical School. From 2001 to 2007 Dr. Samarsky was developing oligonucleotide-based technologies at Sequitur/Invitrogen and Dharmacon/ThermoFisher. Most recently, he was carrying responsibilities for technology and business development at RXi Pharma (2007-2011) and RiboBio Co (2011-present), biopharmaceutical companies developing oligonucleotide-based technologies and therapeutics. Dr. Samarsky co-authored numerous research articles, reviews and book chapters, as well as patents and patent applications. He is a Distinguished Editor for Journal of RNAi and Gene Silencing, and served as advisor, session chair and speaker at more than hundred of scientific conferences around the world.

编辑: tong205    来源:丁香园

主办单位:

中国工程院(CAE)

中国医学科学院(CAMS)

美国国立卫生研究院临床研究中心

协办单位:

上海交通大学

复旦大学

同济大学

上海中医药大学

中国科学院上海生命科学研究院

更多详情>>

5月28日下午:高端论坛

5月28日全天:注册报到

5月29日上午:开幕式、大会报告

5月29日下午:分论坛

5月30日上午:分论坛

5月30日下午:闭幕式